Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of “Moderate Buy” by Analysts

Prime Medicine, Inc. (NYSE:PRME – Get Free Report) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month […]

Leave a Reply

Your email address will not be published.

Previous post Comparing RadNet (NASDAQ:RDNT) & CannLabs (OTCMKTS:CANL)
Next post Brokerages Set RE/MAX Holdings, Inc. (NYSE:RMAX) PT at $15.50